Abstract:Abstract Introduction Parents are increasingly turning to exogenous melatonin to help children sleep, despite a lack of experimental research examining its efficacy and the safety of long-term use. In the U.S., melatonin is classified as a dietary supplement and no prescription is needed to obtain it. Given recent surges in pediatric consumption, current data on the factors contributing to parents’ decisions to administer melatonin to their children are vital in order to understand perceptions and concerns surrounding its use. Methods Parents of 1039 U.S. children ages 1.0-13.9 years completed an online questionnaire on children’s development, sleep health, and melatonin use. Data on 212 children who either took melatonin in the past 30 days (N = 131) or at some point previously (N = 81) were included in the present analysis. Open-ended questions on why parents administered melatonin and why they stopped (if applicable) were categorized through thematic coding. Results Although nearly half of children who recently took melatonin had bedtime resistance (51.1%) or difficulty falling asleep (46.2%), 24.4% had no reported behavioral sleep problems. Parents’ most common reasons for giving melatonin were to help children fall asleep (49.3%) or wind down before bedtime (22.7%). Parents also reported administering it to adjust for changes to regular sleep routines (17.5%) or to shift circadian rhythms (11.4%). Parents frequently reported initiating melatonin on their own (50.0%), with less than half following the recommendation of a healthcare provider (48.1%). Parents often stopped giving melatonin when they felt their child didn’t need it anymore (32.0%). Fewer parents discontinued use due to negative side effects (9.3%) or concerns about health and safety (13.3%). Conclusion Parents reported giving their child melatonin for a variety of reasons related to sleep and circadian timing. Melatonin use was frequently initiated without the recommendation of a medical professional, which raises concerns about misinformation given the gaps in scientific research and variable quality of over-the-counter supplements. Greater research and wider dissemination of guidelines are needed to support parents in making informed decisions regarding their child’s melatonin use. Support (if any) Eunice Kennedy Shriver National Institute of Child Health & Human Development (F32-HD103390; R01-HD087707)

Assessing the potential for drug interactions and long term safety of melatonin for the treatment of insomnia in children with autism spectrum disorder

Insomnia in children affected by autism spectrum disorder: The role of melatonin in treatment

Pediatric Prolonged-Release Melatonin for Sleep in Children with Autism Spectrum Disorder: Impact on Child Behavior and Caregiver’s Quality of Life

Melatonin Treatment and Adequate Sleep Hygiene Interventions in Children with Autism Spectrum Disorder: A Randomized Controlled Trial

Melatonin for sleep disorders in children

Melatonin reverses the decreases in hippocampal protein serine/threonine kinases observed in an animal model of autism.

Melatonin Use in School-Aged Children and Adolescents: An Exploration of Caregiver and Pharmacist Perspectives

Quality of melatonin use in children and adolescents: findings from a UK clinical audit

Melatonin and circadian rhythms in autism: Case report

Melatonin Rhythm and Its Relation to Sleep and Circadian Parameters in Children and Adolescents With Autism Spectrum Disorder

Melatonin and sleep in children with neurodevelopmental disabilities and sleep disorders

Sleeping without Prescription: Management of Sleep Disorders in Children with Autism with Non-Pharmacological Interventions and Over-the-Counter Treatments

Autism Spectrum Disorder (ASD): Disturbance of the Melatonin System and Its Implications

Melatonin Use in Pediatrics: A Clinical Review on Indications, Multisystem Effects, and Toxicity

0817 Influencing Factors in the Decision-Making Process of U.S. Parents Regarding the Use of Melatonin for Children

Pediatric sleep disturbances and treatment with melatonin

Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety

Improvement of sleep and melatonin in children with autism spectrum disorder after β-1,3/1,6-glucan consumption: An open-label prospective pilot clinical study

The therapeutics of melatonin: a paediatric perspective

Sleep Disturbances in Children Affected by Autism Spectrum Disorder

Low Doses of Melatonin to Improve Sleep in Children with ADHD: An Open-Label Trial